title: Interleukin-18 synergism with interleukin-2 in cytotoxicity and NKG2D expression of human natural killer cells.
abstract: Natural killer (NK) cells play an important role in anti-tumor immunity. Interleukin (IL)-18 is an immunoregulatory cytokine that induces potent NK cell-dependent anti-tumor responses when administrated with other cytokines. In this study, we explored the effects of combining IL-18 and IL-2 on NK cytotoxicity as well as expression levels of the NK cell receptor NKG2D in vitro. Freshly isolated PBMCs were incubated for 48 h with IL-18 and IL-2, then CD107a expression on CD3-CD56+ NK cells was determined by three-colour flow cytometry to evaluate the cytotoxicity of NK cells against human erythroleukemia K562 cells and human colon carcinoma HT29 cells. Flow cytometric analysis was also employed to determine NKG2D expression on NK cells. The combined use of IL-18 and IL-2 significantly increased CD107a expression on NK cells compared with using IL-18 or IL-2 alone, suggesting that the combination of these two cytokines exerted synergistic enhancement of NK cytotoxicity. IL-18 also enhanced NKG2D expression on NK cells when administered with IL-2. In addition, blockade of NKG2D signaling with NKG2D-blocking antibody attenuated the up-regulatory effect of combining IL-18 and IL-2 on NK cytolysis. Our data revealed that IL-18 synergized with IL-2 to dramatically enhance the cytolytic activity of human NK cells in a NKG2D-dependent manner. The results appear encouraging for the use of combined IL-18 and IL-2 in tumor immunotherapy.
authors.affiliation: Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to ShandongUniversity, Jinan, Shandong, China E-mail : shenyajuanchina@126.com, luzhiming@sdu.edu.cn.
authors.forename: Yuan-Ying
authors.initials: YY
authors.lastname: Qi
authors.forename: Chao
authors.initials: C
authors.lastname: Lu
authors.forename: Ying
authors.initials: Y
authors.lastname: Ju
authors.forename: Zi-E
authors.initials: ZE
authors.lastname: Wang
authors.forename: Yuan-Tang
authors.initials: YT
authors.lastname: Li
authors.forename: Ya-Juan
authors.initials: YJ
authors.lastname: Shen
authors.forename: Zhi-Ming
authors.initials: ZM
authors.lastname: Lu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D003602:Cytotoxicity, Immunologic; D004357:Drug Synergism; D005434:Flow Cytometry; D006801:Humans; D020382:Interleukin-18 / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000166:cytology / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D052118:Lysosomal-Associated Membrane Protein 1 / Q000378:metabolism; D055655:NK Cell Lectin-Like Receptor Subfamily K / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D020382:Interleukin-18; D007376:Interleukin-2; C527085:KLRK1 protein, human; D052118:Lysosomal-Associated Membrane Protein 1; D055655:NK Cell Lectin-Like Receptor Subfamily K